Search Results for keywords:"false advertising"

The Federal Deposit Insurance Corporation (FDIC) is delaying the full compliance deadline for certain new requirements on how insured banks display membership signs and ads, especially on digital platforms like ATMs and websites. Originally, banks had until May 1, 2025, to comply with these updates, but now they have until March 1, 2026. This delay allows the FDIC time to review feedback on potential issues with implementing these requirements, aiming to prevent consumer confusion. The FDIC plans to propose updates to the rules based on this feedback.

The U.S. International Trade Commission (ITC) is requesting written submissions from parties involved in a case concerning certain eye cosmetics and their packaging. This case involves allegations of unfair practices like trademark infringement and false advertising. Various companies, mostly based abroad, are named as respondents. The ITC is considering potential remedies, including exclusion orders to prevent the entry of these products into the U.S., and is particularly interested in how such actions could impact public interests like health, competition, and consumer choices. The Commission is also inviting comments on bond amounts if a remedy is enforced, and decisions on the case are ongoing.

The Federal Trade Commission has proposed a consent agreement with Chemence, Inc. to address allegations of deceptive practices related to their claims about products being "Made in USA." The FTC found that Chemence falsely advertised their glue products as primarily made in the United States, while much of the materials were sourced from abroad. The proposed order includes a $1.2 million judgment and guidelines for future advertising and compliance measures, including preventing Chemence from making false claims about product origins unless they accurately reflect manufacturing and material sources. This action is part of a shift towards stricter enforcement of "Made in USA" claims, aiming to protect consumers and honest competitors.

The U.S. International Trade Commission (ITC) has decided not to review a decision by an administrative law judge regarding violations of section 337, involving products containing tirzepatide. These violations included trademark infringement, false designation of origin, and false advertising by certain companies. The ITC is now asking for written submissions from different parties on potential remedies, public interests, and bonding issues. If a remedy is ordered, it might include stopping these products from entering the U.S. or cease and desist orders against the companies involved.